Regenerative biotechnology
Gencell® CTM ACE 2+
Pre-stimulated mesenchymal stem cells for pulmonary therapeutic support.
Therapy of mesenchymal stem cells with increased ACE-2 expression, aimed at modulating inflammation, protecting the endothelium, and supporting pulmonary recovery in SARS-CoV-2 infection.
Composition
Mesenchymal stem cells.
Pharmaceutical form
Injectable solution.
Presentation
Monovette with 4 ml.
Therapeutic Properties
They promote tissue repair through immunomodulation, inhibition of apoptosis, stimulation of cellular proliferation, and release of soluble ACE-2, contributing to immune regulation, endothelial protection, and pulmonary recovery.
- Reduction of pulmonary inflammation.
- Modulation of the immune response.
- Inhibition of cellular apoptosis.
- Stimulation of tissue regeneration.
- Transdifferentiation at the site of injury.
- Release of soluble ACE-2.
- Reduction of viral internalization.
- Protection of the pulmonary endothelium.
Mechanism of action & Clinical data
They migrate to injured tissue, modulate inflammation, inhibit apoptosis, stimulate regeneration, and release soluble ACE-2 that reduces SARS-CoV-2 internalization.